Buti M, Esteban R

Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 267-269
Archivo PDF: 91.98 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United states, 1988 through 1994. N Engl J Med 1999; 341: 556-562.2.

2. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999. Journal of Hepatology 1999; 30: 956-96.

3. Anonymous. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C 2002 (June 10-12,2002). Gastroenterology 2002; 123: 2082-2099.

4. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114-S120.

5. McHutchison J, Gordon S, Schiff E, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.

6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.

7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.

8. McHutchison JG, Davis GL, Esteban R, Poynard T, Ling M-H, Garaud J-J, et al. Durability of sustained virological response in patients with chronic hepatitis C after treatment with Interferon alfa 2b alone or in combination with ribavirin. Hepatology 2001; 34: 244A.

9. Lau DT-Y, Kleiner DE, Ghany MC, Park Y, Scmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-1127.

10. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881.

11. Camma C, Di Marco V, Lo Iacono O, Alamasio P, Giunta M, Fuschi P, Vaccaro A, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531-537.

12. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow up of chronic hepatitis C patients with sustained virologic response to alpha-interferon. J Hepatol 1999; 30: 783-787.

13. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688-693.

14. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virology 2004; 78: 5867-5874.

15. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka, J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-114.

16. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600-608.

17. Serang HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United Status. N Engl J Med 199; 340: 745-750.

18. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transplantation 2003; 9: 331-338.

19. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Angel Casado M, Fosbrook L, Esteban R. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.

20. Poynard T, McHutchison J, Davis GL, Esteban R, Goodman Z, Bedosa P, et al. Impact of interferon and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137.

21. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.

22. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk of hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-181.

23. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.

24. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-1875.

25. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.

26. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440.

27. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.